EntryPoint Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

EntryPoint Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$324K	Hold	12,819	–	–	0.08%	513
2026 Q1	$285K	Buy	12,819 +2,474	+24%	+$59.1K	0.08%	487
2025 Q4	$276K	Hold	10,345	–	–	0.11%	397
2025 Q3	$221K	Buy	10,345 +804	+8%	+$19K	0.09%	510
2025 Q2	$206K	Buy	+9,541	New	+$177K	0.1%	472
2025 Q1	–	Sell	-26,022	Closed	-$478K	–	655
2024 Q4	$478K	Buy	26,022 +15,052	+137%	+$243K	0.2%	122
2024 Q3	$169K	Buy	10,970 +3,544	+48%	+$59.1K	0.1%	503
2024 Q2	$121K	Buy	7,426 +2,711	+57%	+$43.8K	0.06%	710
2024 Q1	$87.2K	Sell	4,715 -994	-17%	-$24.6K	0.08%	498
2023 Q4	$179K	Buy	+5,709	New	+$136K	0.17%	122

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

EntryPoint Capital's ACAD Position: Q2 2026 in Review

EntryPoint Capital held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 12,819 shares worth $324K. The position accounts for 0.08% of the portfolio, ranked #513.

EntryPoint Capital first reported a position in ACAD in Q4 2023 and has held it in 10 quarters since. The position peaked at $478K in Q4 2024. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

EntryPoint Capital held 12,819 shares of Acadia Pharmaceuticals worth $324K as of Q2 2026.
EntryPoint Capital left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up 0.08% of EntryPoint Capital's portfolio in Q2 2026, its #513 holding.
EntryPoint Capital first reported a position in Acadia Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
EntryPoint Capital's Acadia Pharmaceuticals position peaked at $478K in Q4 2024.
354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.